Selinexor

Drug Profile

Selinexor

Alternative Names: CRM1 nuclear export inhibitor KPT-330; KPT-330; KPT-330-003; SINE - Karyopharm Therapeutics; SINE KPT 330

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Karyopharm Therapeutics
  • Developer Cardiff University; Dana-Farber Cancer Institute; Erasmus MC; H. Lee Moffitt Cancer Center and Research Institute; Karyopharm Therapeutics; Memorial Sloan-Kettering Cancer Center; National University Hospital (Singapore); Rigshospitalet; Sheba Medical Center; St. Jude Childrens Research Hospital; The Ohio State University Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center; Weill Cornell Medical College
  • Class Acrylamides; Antineoplastics; Hydrazines; Pyrazines; Small molecules
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma; Soft tissue sarcoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Liposarcoma; Multiple myeloma
  • Phase II Acute myeloid leukaemia; Breast cancer; Cervical cancer; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Endometrial cancer; Glioblastoma; Myelodysplastic syndromes; Neuroendocrine tumours; Ovarian cancer; Peripheral T-cell lymphoma; Prostate cancer; Small cell lung cancer; Squamous cell cancer; Thymoma
  • Phase I/II Acute lymphoblastic leukaemia; Chronic myelomonocytic leukaemia
  • Phase I B cell lymphoma; Chronic lymphocytic leukaemia; Colorectal cancer; Diabetic foot ulcer; Gastric cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Rectal cancer; Solid tumours
  • Preclinical Non-small cell lung cancer
  • Research Osteosarcoma

Most Recent Events

  • 04 Dec 2016 Efficacy and updated adverse event data from a phase IIb STORM trial in Multiple myeloma (Combination therapy, Refractory metastatic disease) presented at the 58th Annual Meeting of the American Society of Haematology (ASH–2016)
  • 04 Dec 2016 Interim adverse events and efficacy data from the phase II SAIL trial in Acute myeloid leukaemia presented at the 58th Annual Meeting of the American Society of Haematology (ASH–2016)
  • 03 Nov 2016 Interim efficacy and adverse events data from a phase IIb STORM trial in Multiple myeloma (Combination therapy, Refractory metastatic disease) released by Karyopharm Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top